OA13013A - Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. - Google Patents

Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. Download PDF

Info

Publication number: OA13013A
Authority: OA; OAPI
Prior art keywords: degrees; expressed; strontium ranelate; strokes; crystalline form
Prior art date: 2004-09-30

Application number

OA1200500169A

Other languages

English (en)

French (fr)

Inventor

Stephane Horvath

Isabelle Demuynck

Gerard Damien

Original Assignee

Laboratiores Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-06-02

Publication date

2006-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-02 Application filed by Laboratiores Servier filed Critical Laboratiores Servier

2006-11-10 Publication of OA13013A publication Critical patent/OA13013A/fr

Links

229940079488 strontium ranelate Drugs 0.000 title claims abstract description 19
238000002360 preparation method Methods 0.000 title claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
238000000034 method Methods 0.000 title claims description 6
XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 title abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 5
231100000252 nontoxic Toxicity 0.000 claims abstract description 4
230000003000 nontoxic effect Effects 0.000 claims abstract description 4
ZHEZAQJNZMLYBA-UHFFFAOYSA-J distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N ZHEZAQJNZMLYBA-UHFFFAOYSA-J 0.000 claims description 18
238000001914 filtration Methods 0.000 claims description 5
150000004677 hydrates Chemical class 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
201000008482 osteoarthritis Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
238000002425 crystallisation Methods 0.000 claims description 2
230000008025 crystallization Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
208000001132 Osteoporosis Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000004689 octahydrates Chemical class 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000003262 anti-osteoporosis Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004688 heptahydrates Chemical class 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
DJSXNILVACEBLP-UHFFFAOYSA-N ranelic acid Chemical compound OC(=O)CN(CC(O)=O)C=1SC(C(O)=O)=C(CC(O)=O)C=1C#N DJSXNILVACEBLP-UHFFFAOYSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Fodder In General (AREA)

OA1200500169A 2004-09-30 2005-06-02 Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. OA13013A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0410335A FR2875807B1 (fr)	2004-09-30	2004-09-30	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
OA13013A true OA13013A (fr)	2006-11-10

Family

ID=34942420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500169A OA13013A (fr)	2004-09-30	2005-06-02	Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent.

Country Status (41)

Country	Link
US (2)	US7459568B2 (sr)
EP (2)	EP1944302A1 (sr)
JP (2)	JP2006104184A (sr)
KR (1)	KR100816590B1 (sr)
CN (1)	CN100391956C (sr)
AP (1)	AP1930A (sr)
AR (1)	AR049395A1 (sr)
AT (1)	ATE411308T1 (sr)
AU (1)	AU2005202718B2 (sr)
BR (1)	BRPI0502228A (sr)
CA (1)	CA2508824C (sr)
CO (1)	CO5710195A1 (sr)
CR (1)	CR7876A (sr)
CY (1)	CY1108797T1 (sr)
DE (1)	DE602005010359D1 (sr)
DK (1)	DK1642897T3 (sr)
EA (1)	EA008474B1 (sr)
EC (1)	ECSP055859A (sr)
ES (1)	ES2314593T3 (sr)
FR (1)	FR2875807B1 (sr)
GE (1)	GEP20074106B (sr)
GT (1)	GT200500130A (sr)
HR (1)	HRP20080652T3 (sr)
IL (1)	IL169237A (sr)
MA (1)	MA27815A1 (sr)
MX (1)	MXPA05006407A (sr)
NO (1)	NO333948B1 (sr)
NZ (1)	NZ540802A (sr)
OA (1)	OA13013A (sr)
PA (1)	PA8638201A1 (sr)
PE (1)	PE20060364A1 (sr)
PL (1)	PL1642897T3 (sr)
PT (1)	PT1642897E (sr)
RS (1)	RS51110B (sr)
SA (1)	SA05260168B1 (sr)
SG (1)	SG121035A1 (sr)
SI (1)	SI1642897T1 (sr)
TW (1)	TWI367881B (sr)
UA (1)	UA80008C2 (sr)
WO (1)	WO2006035122A1 (sr)
ZA (1)	ZA200504937B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292535A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating osteoporotic conditions
CN101206208B (zh) *	2006-12-19	2011-08-10	北京德众万全药物技术开发有限公司	一种用hplc法分析雷尼酸锶原料及其制剂的方法
CN102227419A (zh) *	2008-09-29	2011-10-26	拉蒂奥法姆有限责任公司	无水和水合形式的雷奈酸锶
IT1398542B1 (it)	2010-03-05	2013-03-01	Chemelectiva S R L	Processo per la preparazione di un polimorfo
CN102241663B (zh) *	2010-05-10	2013-02-13	山东方明药业集团股份有限公司	一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) *	2011-04-21	2012-10-26	Shilpa Medicare Limited	Crystalline strontium ranelate form-s
CZ2011320A3 (cs)	2011-05-30	2012-12-12	Zentiva, K.S.	Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en)	2011-05-31	2012-12-05	Lacer, S.A.	New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en)	2011-07-21	2013-01-24	Emory University	Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) *	2011-09-20	2012-06-20	浙江华海药业股份有限公司	一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) *	2012-01-31	2013-08-08	Pharmathen S.A.	Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en)	2012-03-23	2013-09-25	Urquima S.A.	Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en)	2012-05-17	2013-10-29	Divi's Laboratories, Ltd.	Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2651497B1 (fr) *	1989-09-01	1991-10-25	Adir	Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
UA41909C2 (uk)	1994-07-22	2001-10-15	Елі Ліллі Енд Компані	Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
ES2272781T5 (es) *	2001-10-03	2010-04-06	Teva Pharmaceutical Industries Ltd.	Preparacion de levofloxacino hemihidratado.
EP1469827B1 (en) *	2002-01-09	2017-12-27	Emisphere Technologies, Inc.	Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate
PL374993A1 (en) *	2002-08-06	2005-11-14	Teva Pharmaceutical Industries Ltd.	Novel crystalline forms of gatifloxacin
FR2844797B1 (fr)	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr)	2002-09-24	2004-03-26	Servier Lab	Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr not_active Ceased
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de not_active Expired - Lifetime
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es not_active Expired - Lifetime
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active Expired - Fee Related
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending

Also Published As

Publication number	Publication date
SA05260168B1 (ar)	2009-02-25
HK1086260A1 (zh)	2006-09-15
GT200500130A (es)	2005-12-20
EA008474B1 (ru)	2007-06-29
CO5710195A1 (es)	2006-12-29
RS51110B (sr)	2010-10-31
AP1930A (en)	2008-12-15
DK1642897T3 (da)	2009-01-26
CA2508824A1 (fr)	2006-03-30
CA2508824C (fr)	2009-03-24
AP2005003323A0 (en)	2005-06-30
CN100391956C (zh)	2008-06-04
PL1642897T3 (pl)	2009-04-30
AU2005202718B2 (en)	2010-09-16
NO20052998D0 (no)	2005-06-17
US7745482B2 (en)	2010-06-29
AR049395A1 (es)	2006-07-26
AU2005202718A1 (en)	2006-04-13
BRPI0502228A (pt)	2006-05-09
PT1642897E (pt)	2008-11-27
KR20060049966A (ko)	2006-05-19
ECSP055859A (es)	2006-09-18
CY1108797T1 (el)	2014-04-09
KR100816590B1 (ko)	2008-03-24
HRP20080652T3 (en)	2009-01-31
US7459568B2 (en)	2008-12-02
EP1944302A1 (fr)	2008-07-16
PA8638201A1 (es)	2006-05-16
EP1642897B9 (fr)	2009-08-12
FR2875807A1 (fr)	2006-03-31
WO2006035122A1 (fr)	2006-04-06
SI1642897T1 (sl)	2009-02-28
EP1642897A1 (fr)	2006-04-05
ZA200504937B (en)	2006-04-26
ATE411308T1 (de)	2008-10-15
NZ540802A (en)	2006-11-30
US20080312314A1 (en)	2008-12-18
NO333948B1 (no)	2013-10-28
TW200610758A (en)	2006-04-01
TWI367881B (en)	2012-07-11
UA80008C2 (uk)	2007-08-10
IL169237A (en)	2010-12-30
CN1754878A (zh)	2006-04-05
MXPA05006407A (es)	2006-04-05
DE602005010359D1 (de)	2008-11-27
GEP20074106B (en)	2007-05-10
EP1642897B1 (fr)	2008-10-15
ES2314593T3 (es)	2009-03-16
CR7876A (es)	2007-12-10
US20060069271A1 (en)	2006-03-30
MA27815A1 (fr)	2006-04-03
FR2875807B1 (fr)	2006-11-17
SG121035A1 (en)	2006-04-26
JP2010132669A (ja)	2010-06-17
JP2006104184A (ja)	2006-04-20
PE20060364A1 (es)	2006-06-17
NO20052998L (no)	2006-03-31
EA200500842A1 (ru)	2006-04-28

Publication	Publication Date	Title
CA2537414C (fr)	2010-02-16	Forme cristalline .beta. du chlorhydrate de l'ivrabadine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537400C (fr)	2009-12-15	Forme cristalline .gamma. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537420C (fr)	2010-03-30	Forme cristalline bd du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537404C (fr)	2010-04-13	Forme cristalline .gamma.-d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2564367C (fr)	2010-05-18	Forme cristalline .delta. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2564369C (fr)	2010-06-15	Forme cristalline .delta.d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
OA13013A (fr)	2006-11-10	Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent.
FR2811320A1 (fr)	2002-01-11	Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
WO2001083439A2 (fr)	2001-11-08	NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
EP1294689A1 (fr)	2003-03-26	Nouvelle forme cristalline $g(b) du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR3025197B1 (fr)	2019-09-06	Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK1096659B (en)	2009-01-23	γ-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT